Related Experiment Video

Updated: Sep 23, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.0K

DUSP4 protects BRAF- and NRAS-mutant melanoma from oncogene overdose through modulation of MITF

Nuria Gutierrez-Prat1, Hedwig L Zuberer1, Luca Mangano1

  • 1Roche Pharma Research and Early Development, Oncology Discovery, Roche Innovation Center Basel, Basel, Switzerland.

Life Science Alliance
|May 17, 2022
PubMed

Insights

Targeting DUSP4 may overcome resistance to MAPK inhibitors (MAPKi) in metastatic melanoma. Depleting DUSP4 causes toxic MAPK activation, offering new therapeutic strategies for melanoma patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • MAPK inhibitors (MAPKi) are standard care for metastatic melanoma but acquired resistance limits efficacy.
  • Resistance often involves ERK reactivation, leading to a 'drug addiction' phenotype and sensitivity to drug withdrawal.
  • The specific genes controlling oncogene overdose in melanoma remain largely unknown.

Purpose of the Study:

  • To identify key regulators of oncogene overdose in mutant melanoma.
  • To investigate the role of DUSP4 in MAPK signaling and drug resistance.
  • To explore DUSP4 as a potential therapeutic target in melanoma.

Main Methods:

  • Depletion of DUSP4 in drug-naive and drug-resistant melanoma cell lines.
  • Analysis of MAPK/ERK pathway activation.
  • Assessment of lineage-defining gene expression, including MITF.

Main Results:

  • DUSP4 depletion induced toxic levels of MAPK activation in melanoma cells.
  • ERK hyperactivation correlated with the downregulation of MITF and other lineage-defining genes.
  • This suggests DUSP4 is a critical gatekeeper of oncogene overdose.

Conclusions:

  • DUSP4 acts as a crucial regulator of oncogene overdose in melanoma.
  • Targeting DUSP4 presents a novel therapeutic strategy for melanoma patients with acquired MAPKi resistance.
  • This approach may also benefit patients intolerant to current MAPKi treatments.

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.1K
Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.2K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K